TELA Bio(TELA) - 2024 Q4 - Earnings Call Presentation

Company Overview - TELA Bio provides innovative soft-tissue reconstruction solutions prioritizing the preservation and restoration of the patient's own anatomy[4] - The company operates in a $2.6 billion US market opportunity that is still in early stages of growth[7] - The company has implanted over 65,000 OviTex Reinforced Tissue Matrix (RTM) globally[9] and approximately 15,000 OviTex PRS implants globally[10] Hernia Repair Market - The US hernia surgery market represents an approximately $1.8 billion annual opportunity[7, 12] - Robotic/MIS compatible procedures within the hernia market total over 1 million annually, representing a potential market opportunity of up to $1.2 billion[14] - 59% of surgeons agree that the use of permanent synthetic mesh puts patients at long-term risk of complications[23] OviTex Clinical Performance - BRAVO study showed a low recurrence rate of 2.6% at 24 months using OviTex in ventral hernia repair[30] - OviTex patients experienced significantly fewer complications than patients receiving other three biologics[29] - OviTex and Strattice patients had a statistically lower recurrence rate than patients receiving the other two biologics[29] Financial Performance - Q4 2024 revenue reached $17.6 million, a 4% increase over the corresponding period in 2023[59] - The company's gross margin in Q4 2024 was 64%[58] - The company had $52.7 million in cash and cash equivalents as of December 31, 2024[59]